Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Total Assets of $448.38 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $448.38M | +172.9% |
| 2024 | $164.30M | +49255.4% |
| 2023 | $332.9K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $484.79M | +152.1% | +145.6% |
| June 30, 2025 | $197.39M | +4.0% | +0.9% |
| March 31, 2025 | $195.68M | +4.3% | +19.1% |
| December 31, 2024 | $164.30M | +49255.4% | -14.6% |
| September 30, 2024 | $192.33M | — | +1.3% |
| June 30, 2024 | $189.87M | — | +1.3% |
| March 31, 2024 | $187.53M | — | +56232.9% |
| December 31, 2023 | $332.9K | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +172.9% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, BridgeBio Oncology Therapeutics, Inc.’s total assets has grown by 134591.8% (from $332.9 thousand to $448.38 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: